Year |
Citation |
Score |
2023 |
Trinh D, Israwi AR, Brar H, Villafuerte JEA, Laylo R, Patel H, Jafri S, Al Halabi L, Sinnathurai S, Reehal K, Shi A, Gnanamanogaran V, Garabedian N, Thrasher D, Monnier PP, ... ... Nash JE, et al. Parkinson's disease pathology is directly correlated to SIRT3 in human subjects and animal models: Implications for AAV.SIRT3-myc as a disease-modifying therapy. Neurobiology of Disease. 106287. PMID 37704058 DOI: 10.1016/j.nbd.2023.106287 |
0.32 |
|
2020 |
Trinh D, Israwi AR, Arathoon LR, Gleave JA, Nash JE. The multi-faceted role of mitochondria in the pathology of Parkinson's disease. Journal of Neurochemistry. PMID 33616931 DOI: 10.1111/Jnc.15154 |
0.44 |
|
2018 |
Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JEM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE. Corrigendum to "Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism" [Neurobiol. Dis. 106 (2018) 133-146]. Neurobiology of Disease. PMID 29571591 DOI: 10.1016/J.Nbd.2018.02.018 |
0.723 |
|
2017 |
Lu JYD, Su P, Barber JEM, Nash JE, Le AD, Liu F, Wong AHC. The neuroprotective effect of nicotine in Parkinson's disease models is associated with inhibiting PARP-1 and caspase-3 cleavage. Peerj. 5: e3933. PMID 29062606 DOI: 10.7717/Peerj.3933 |
0.4 |
|
2017 |
Arathoon LR, Gleave JA, Trinh D, Lizal KE, Giguère N, Barber JHM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE. Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism. Neurobiology of Disease. PMID 28673739 DOI: 10.1016/J.Nbd.2017.06.009 |
0.746 |
|
2014 |
Thiele SL, Chen B, Lo C, Gertler TS, Warre R, Surmeier JD, Brotchie JM, Nash JE. Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models. Neurobiology of Disease. 71: 334-44. PMID 25171793 DOI: 10.1016/J.Nbd.2014.08.006 |
0.722 |
|
2014 |
Gleave JA, Perri PD, Nash JE. Mitochondrial dysfunction in Parkinson’s disease: a possible target for neuroprotection Frontiers in Biology. 9: 489-503. DOI: 10.1007/S11515-014-1337-8 |
0.319 |
|
2012 |
Yong-Kee CJ, Warre R, Monnier PP, Lozano AM, Nash JE. Evidence for synergism between cell death mechanisms in a cellular model of neurodegeneration in parkinson's disease Neurotoxicity Research. 22: 355-364. PMID 22528248 DOI: 10.1007/S12640-012-9325-8 |
0.393 |
|
2012 |
Thiele SL, Warre R, Nash JE. Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease. Journal of Visualized Experiments : Jove. PMID 22370630 DOI: 10.3791/3234 |
0.742 |
|
2012 |
Johnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, Yong-Kee CJ, Gandy MN, McIldowie M, Lewis KD, Gomez-Ramirez J, Lee J, Fox SH, Martin-Iverson M, Nash JE, et al. A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 2154-63. PMID 22345403 DOI: 10.1096/Fj.11-195016 |
0.731 |
|
2012 |
Yong-Kee CJ, Sidorova E, Hanif A, Perera G, Nash JE. Mitochondrial dysfunction precedes other sub-cellular abnormalities in an in vitro model linked with cell death in Parkinson's disease. Neurotoxicity Research. 21: 185-94. PMID 21773851 DOI: 10.1007/S12640-011-9259-6 |
0.422 |
|
2011 |
Thiele SL, Warre R, Khademullah CS, Fahana N, Lo C, Lam D, Talwar S, Johnston TH, Brotchie JM, Nash JE. Generation of a model of L-DOPA-induced dyskinesia in two different mouse strains. Journal of Neuroscience Methods. 197: 193-208. PMID 21352853 DOI: 10.1016/J.Jneumeth.2011.02.012 |
0.735 |
|
2011 |
Appleby VJ, Corrêa SA, Duckworth JK, Nash JE, Noël J, Fitzjohn SM, Collingridge GL, Molnár E. LTP in hippocampal neurons is associated with a CaMKII-mediated increase in GluA1 surface expression. Journal of Neurochemistry. 116: 530-43. PMID 21143596 DOI: 10.1111/J.1471-4159.2010.07133.X |
0.315 |
|
2011 |
Warre R, Thiele S, Talwar S, Kamal M, Johnston TH, Wang S, Lam D, Lo C, Khademullah CS, Perera G, Reyes G, Sun XS, Brotchie JM, Nash JE. Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism. Neurobiology of Disease. 41: 591-604. PMID 20971190 DOI: 10.1016/J.Nbd.2010.10.013 |
0.741 |
|
2011 |
Yong-Kee CJ, Salomonczyk D, Nash JE. Development and validation of a screening assay for the evaluation of putative neuroprotective agents in the treatment of Parkinson's disease Neurotoxicity Research. 19: 519-526. PMID 20361292 DOI: 10.1007/S12640-010-9174-2 |
0.391 |
|
2010 |
Nash JE, Appleby VJ, Corrêa SA, Wu H, Fitzjohn SM, Garner CC, Collingridge GL, Molnár E. Disruption of the interaction between myosin VI and SAP97 is associated with a reduction in the number of AMPARs at hippocampal synapses. Journal of Neurochemistry. 112: 677-90. PMID 19895665 DOI: 10.1111/J.1471-4159.2009.06480.X |
0.327 |
|
2010 |
Gandy MN, McIldowie M, Lewis K, Wasik AM, Salomonczyk D, Wagg K, Millar ZA, Tindiglia D, Huot P, Johnston T, Thiele S, Nguyen B, Barnes NM, Brotchie JM, Martin-Iverson MT, ... Nash J, et al. Redesigning the designer drug ecstasy: Non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity Medchemcomm. 1: 287-293. DOI: 10.1039/C0Md00108B |
0.702 |
|
2005 |
Nash JE, Johnston TH, Collingridge GL, Garner CC, Brotchie JM. Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 19: 583-5. PMID 15703272 DOI: 10.1096/fj.04-1854fje |
0.371 |
|
2004 |
Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Experimental Neurology. 188: 471-9. PMID 15246846 DOI: 10.1016/J.Expneurol.2004.05.004 |
0.38 |
|
2004 |
Kalia SK, Nash JE, Lozano AM. To serve and protect? Interventions in the subthalamic nucleus for Parkinson's disease. Commentary on "Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease". Experimental Neurology. 185: 201-3. PMID 14736500 DOI: 10.1016/J.Expneurol.2003.10.005 |
0.392 |
|
2002 |
Nash JE, Brotchie JM. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 455-66. PMID 12112191 DOI: 10.1002/Mds.10107 |
0.381 |
|
2002 |
Zamani MR, Leeson AH, Nash J, Bristow DR. Histamine induces the phosphorylation of a 58 kDa protein in GT1-7 neuronal cells Neuroscience Research Communications. 31: 11-18. DOI: 10.1002/Nrc.10033 |
0.308 |
|
2000 |
Nash JE, Brotchie JM. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 7782-9. PMID 11027242 DOI: 10.1523/Jneurosci.20-20-07782.2000 |
0.323 |
|
2000 |
Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Experimental Neurology. 165: 136-42. PMID 10964492 DOI: 10.1006/Exnr.2000.7444 |
0.426 |
|
1999 |
Nash JE, Hill MP, Brotchie JM. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Experimental Neurology. 155: 42-8. PMID 9918703 DOI: 10.1006/Exnr.1998.6963 |
0.377 |
|
Low-probability matches (unlikely to be authored by this person) |
2002 |
Wu H, Nash JE, Zamorano P, Garner CC. Interaction of SAP97 with minus-end-directed actin motor myosin VI. Implications for AMPA receptor trafficking. The Journal of Biological Chemistry. 277: 30928-34. PMID 12050163 DOI: 10.1074/Jbc.M203735200 |
0.267 |
|
2000 |
Garner CC, Nash J, Huganir RL. PDZ domains in synapse assembly and signalling. Trends in Cell Biology. 10: 274-80. PMID 10856930 DOI: 10.1016/S0962-8924(00)01783-9 |
0.262 |
|
2003 |
Fenster SD, Kessels MM, Qualmann B, Chung WJ, Nash J, Gundelfinger ED, Garner CC. Interactions between Piccolo and the actin/dynamin-binding protein Abp1 link vesicle endocytosis to presynaptic active zones. The Journal of Biological Chemistry. 278: 20268-77. PMID 12654920 DOI: 10.1074/Jbc.M210792200 |
0.256 |
|
1996 |
Maneuf YP, Nash JE, Crossman AR, Brotchie JM. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. European Journal of Pharmacology. 308: 161-4. PMID 8840127 DOI: 10.1016/0014-2999(96)00326-3 |
0.237 |
|
2022 |
Trinh D, Nash J, Goertz D, Hynynen K, Bulner S, Iqbal U, Keenan J. Microbubble drug conjugate and focused ultrasound blood brain barrier delivery of AAV-2 SIRT-3. Drug Delivery. 29: 1176-1183. PMID 35393905 DOI: 10.1080/10717544.2022.2035855 |
0.098 |
|
Hide low-probability matches. |